Nancy Krieger - Sep 10, 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TALS)

Role: Chief Medical Officer
Signature: /s/ Mary Kay Fenton, attorney-in-fact
Stock symbol: TALS
Transactions as of: Sep 10, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/13/2022, 04:30 PM
Previous filing: Feb 2, 2022
Next filing: Feb 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TALS	Common Stock	Award	$0	+80K	+31.97%	$0.00	330K	Sep 10, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date.

Content

The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date.